On August 10, 2026, Northwestern Medicine and Structure Therapeutics released Phase 2b results showing that adults with obesity or overweight who took the highest dose of aleniglipron, an oral small-molecule GLP-1 receptor agonist, lost an average of 12.1% of their body weight over 36 weeks, compared with 0.5% in the placebo group. The drug, developed under the research code GSBR-1290, requires no refrigeration, no injection, and no fasting window, removing three logistical barriers that have kept injectable GLP-1 therapies such as semaglutide out of reach for patients in primary-care clinics without cold-chain infrastructure and for those who decline needle-based treatment. The data, published in Nature Medicine and reported by ScienceDaily, place aleniglipron in a narrow but growing class of orally administered, chemically synthesized GLP-1 agonists that could reduce dependence on the biologic manufacturing pipelines currently constraining global supply of weight loss peptides.
Robert Kushner, professor emeritus of medicine in the Division of Endocrinology, Metabolism and Molecular Medicine at Northwestern University Feinberg School of Medicine and a co-author of the study, framed the distinction in chemical rather than clinical terms. "The difference with aleniglipron is it's a small molecule, which means it's chemically made and could be taken with or without food," Kushner said in the Northwestern release. Injectable GLP-1 drugs such as Ozempic and Wegovy are peptide-based biologics that must be refrigerated, administered by subcutaneous injection, and produced through complex cell-culture processes that limit output volume. Aleniglipron, by contrast, can be synthesized through standard chemical routes, a property that Structure Therapeutics has cited as a path toward lower per-unit manufacturing cost.
Trial Design and Dose-Response Data
Figure 1: The infographic compares placebo-adjusted weight loss across oral aleniglipron dose cohorts with the logistical barriers separating small-molecule tablets from injectable peptide GLP-1 therapies.
Julio Rosenstock, director of the Dallas Diabetes Research Center at Medical City and clinical professor at UT Southwestern Medical Center, presented the ACCESS trial findings at the 2026 American Diabetes Association Scientific Sessions in New Orleans. The 230 enrolled participants had a mean body-mass index of 39.5 kg/m², a mean body weight of 114.8 kg, and a mean age of 49.8 years; 54% were female. Eligible adults had a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition such as hypertension, dyslipidemia, obstructive sleep apnea, or metabolic dysfunction-associated steatohepatitis.
Investigators randomized participants in a 3:1 ratio to aleniglipron or placebo within three dose cohorts of 45 mg, 90 mg, and 120 mg. All active-treatment arms began at 5 mg and titrated upward every four weeks. Placebo-adjusted weight reductions at 36 weeks were 8.2% in the 45-mg group, 9.8% in the 90-mg group, and 11.3% in the 120-mg group, as detailed in Drug Topics' coverage of the publication. No weight-loss plateau was apparent at the end of the double-blind period. In a prespecified interim analysis of the open-label extension conducted at a median 56-week follow-up, mean weight loss from randomization reached 13.3%, 16.2%, and 15.3% in the three dose groups respectively. Participants in the active arms also showed reductions in systolic and diastolic blood pressure and in hemoglobin A1c, with no evidence of QTc prolongation.
Gastrointestinal Tolerability and the Access Question
The most frequently reported treatment-emergent adverse events were gastrointestinal, consistent with the GLP-1 receptor-agonist class. Nausea occurred in up to 71.1% of participants at the 45-mg dose, and vomiting reached 44.6% at 90 mg. Diarrhea and constipation also appeared across dose cohorts. These rates align with those seen in approved injectable GLP-1 therapies and tended to decrease over the titration period, though the 230-person sample limits the ability to detect rarer safety signals. The trial was conducted at 38 U.S. clinical sites, and the drug has not received approval from the Food and Drug Administration or any other regulatory agency.
The access implications of the small-molecule format extend beyond individual convenience. Injectable GLP-1 peptides require refrigerated distribution, trained administration, and multi-step supply chains that are difficult to maintain in rural health centers, community clinics in low-income countries, and conflict-affected settings. A chemically stable tablet that can be stored at room temperature and self-administered removes those dependencies. For populations who currently access oral peptides only through informal or unregulated channels, a formally approved small-molecule alternative could shift treatment into supervised clinical settings. Raymond Stevens, CEO of Structure Therapeutics, said the Phase 2 program demonstrated "clear differentiation of aleniglipron, with the highest weight loss observed for an oral GLP-1 RA to date and a safety profile appropriate for chronic use." The company separately reported topline data in March 2026 from ACCESS II, a 44-week trial evaluating aleniglipron doses up to 240 mg, though full peer-reviewed results from that study have not yet been published.
What the Trial Does Not Yet Show
The ACCESS study was a Phase 2b dose-finding trial, not a registration trial. Its 230 participants, drawn exclusively from U.S. clinical sites, do not represent the age, ethnic, and comorbidity diversity of the global obesity population. The mean age of 49.8 years and the U.S.-only enrollment mean that efficacy and safety in older adults, in adolescents, and in populations with different genetic backgrounds or concurrent medication profiles remain uncharacterized. No head-to-head comparison against injectable semaglutide or tirzepatide was conducted; the 12.1% figure is a placebo-adjusted result within this single trial, not a non-inferiority finding against an approved comparator.
Cost and pricing data do not yet exist. Structure Therapeutics has described the small-molecule chemistry as more amenable to scale manufacturing, but no published analysis projects a per-course price, and no insurance-coverage or national-formulary decision has been made. The gap between a molecule that is cheaper to produce and one that is affordable to the patient at the pharmacy counter or in a district hospital has not been bridged by any GLP-1 therapy to date. Whether the manufacturing advantage translates into lower prices and wider geographic availability, as researchers and clinicians have noted, remains untested until regulatory and pricing decisions are made.
Aleniglipron now enters Phase 3 evaluation under the ACCOMPLISH-1 protocol. Structure Therapeutics has not publicly named a target filing date with the FDA or the European Medicines Agency. Until larger, multi-country registration trials confirm the 36-week signal and regulators assess the chronic-use safety profile, the drug remains unavailable to any patient outside a clinical protocol. The 230 adults enrolled in ACCESS will continue to be followed in the open-label extension, and their longer-term data will form part of the evidence package that regulators review before any approval decision.
